South Korean startup DECANT has succeeded in bio-recycling tens of millions of tons of wine-making by-products that were being wasted annually into high-value-added beauty products.
Using green decanting technology, the company has developed a variety of beauty products made of pomace, a collective term for grape seeds, stems, and skins generated during the wine extraction process.
VINOIR, the company's green beauty brand, has already established a presence on Amazon and is set to debut in the domestic market in the second half of this year.
DECANT's acquisition of wineries in Tasmania, Australia, and pomace from Bourgogne, France, ensured its global competitiveness.
Due to technical difficulties and processing difficulties, pomace, a by-product generated during the winemaking process, has been wasted.
Pomace has long been considered a significant environmental threat because it produces carbon and acidifies soils.


Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions
GesiaPlatform Launches Carbon-Neutral Lifestyle App ‘Net Zero Heroes’
UK Starting Salaries See Strongest Growth in 18 Months as Hiring Sentiment Improves
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Ukraine minerals deal: the idea that natural resource extraction can build peace has been around for decades
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
How is Antarctica melting, exactly? Crucial details are beginning to come into focus
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Fungi are among the planet’s most important organisms — yet they continue to be overlooked in conservation strategies
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 



